You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

ANG Lifesciences spurts after acquisition

Capital Market 

ANG Lifesciences India hit an upper circuit limit of 5% at Rs 521.65 after the company said it will invest in the equity shares of ANG Healthcare India.

ANG Lifesciences India will acquire 2.6 lakh equity shares of ANG Healthcare India for approximately Rs 4 crore. Following the acquisition of 100% stake, ANG Healthcare India will become wholly-owned subsidiary of ANG Lifesciences India.

ANG Healthcare India is a marketing company selling critical care products to hospitals and nursing homes in therapeutic segments of anti-biotic, anti-infective, anti-malarial, pain management etc. The company has got presence all over India through a network of super stockists and 150 stockists along with a strong sales force of about 60 personnel and expanding at a fast pace.

"The acquisition will help company in its brand-building, domestic branding and direct marketing initiative for the purposes of staying close to the customer," ANG Lifesciences India said in a statement.

ANG Healthcare India was incorporated on 25 April 2016. In FY 2021-22, it reported revenue of Rs 16 crore.

ANG Lifesciences India is pharmaceutical manufacturing company. Its product portfolio includes dry powder injection, liquid injection, hard gelatin capsule, tablet beta lactum, tablets, liquid suspension/syrup, ointment/creams and soft gelatin capsules.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 24 2021. 14:43 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU